$0.50
Today
as of Sep 4, 16:46 ET
Last 30 days
Recent Press Releases & News
aTyr Pharma Updates Timing of FDA Response for Planned Phase 3 Trial of Efzofitimod
aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans
Overview
52-week range
$0.40
$6.50
2% of range
Avg surprise (last 3)
+6.5%
Avg reaction (last 2)
-6.1%
0% positive
Latest IV / EM
145%
EM ±27.8% · $1 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.11 | — | — | — | — | financials |
| Fri May 15, 2026 | Mar/2026 | $-0.11 | $-0.16 | +31.2% | +35.3% | -10.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.26 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.22 | $-0.18 | -22.2% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $-0.17 | $-0.19 | +10.5% | — | -2.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.23 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.23 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.23 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.20 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.22 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.29 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $190,000 | $0 | $0 | — | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-11M | $-11M | — | $-27M | $-20M | $-16M | — | $-18M |
| Net income | $-10M | $-11M | — | $-26M | $-20M | $-15M | — | $-17M |
| EPS (diluted) | $-0.11 | $-0.11 | — | $-0.26 | $-0.22 | $-0.17 | — | $-0.23 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $16M | $10M | $11M | $6M | $17M | $10M | $11M | $11M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $58M | $68M | $80M | $93M | $87M | $83M | $82M | $76M |
| Total assets | $70M | $80M | $93M | $107M | $102M | $97M | $97M | $92M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $49M | $58M | $67M | $80M | $75M | $75M | $70M | $65M |